By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Revance Therapeutics, Inc. 

7555 Gateway Boulevard

Newark  California  94560  U.S.A.
Phone: 510-742-3400 Fax: 510-742-3401


Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through a novel drug product candidate, an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. Revance is pursuing clinical development for drug product candidate injectable RT002 in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT002 and the TransMTS technology platform.

Key Statistics

Ownership: Public

Web Site: Revance
Employees: 100+
Symbol: RVNC

Company News
Revance (RVNC) To Release Second Quarter 2016 Financial Results Thursday, August 4, 2016 7/22/2016 7:43:48 AM
Revance (RVNC) Announces Completion Of Pre-Phase 3 Meeting With FDA For RT002 Injectable To Treat Glabellar Lines 7/15/2016 11:18:51 AM
Revance (RVNC) Appoints Industry Leader Julian S. Gangolli To Its Board Of Directors 7/5/2016 8:06:20 AM
Once Floated as Allergan (AGN) Target, Revance (RVNC)'s Stock Drops as Crow’s Feet Drug Fails Trial 6/14/2016 9:15:59 AM
Revance Therapeutics, Inc. (RVNC) To Release Fourth Quarter And Full Year 2015 Financial Results Wednesday, March 2, 2016 2/18/2016 8:19:27 AM
Revance Therapeutics, Inc. (RVNC) Specifies 2016 Clinical Program Milestones 1/8/2016 7:58:58 AM
Revance Therapeutics, Inc. (RVNC) Appoints Abhay Joshi, PhD, as Chief Operating Officer 12/15/2015 8:30:55 AM
Revance Therapeutics (RVNC) To Present In The 27th Annual Piper Jaffray Healthcare Conference 11/20/2015 8:03:33 AM
Revance Therapeutics (RVNC) Releases Third Quarter 2015 Results 11/10/2015 7:58:19 AM
Revance Therapeutics (RVNC) Announces Closing Of Public Offering Of Common Stock 11/9/2015 10:17:32 AM